What is the recommended management for alcoholic hepatitis, including abstinence, nutrition, and pharmacologic therapy?

Management of Alcoholic Hepatitis

Abstinence from alcohol is the absolute cornerstone of treatment for all patients with alcoholic hepatitis, combined with aggressive nutritional support (1-1.5 g protein and 30-40 kcal/kg body weight daily), and prednisolone 40 mg daily for severe disease (MDF ≥32 or MELD >20) without contraindications to corticosteroids. 1

Initial Assessment and Severity Stratification

Severity scoring is mandatory to guide treatment decisions. Use one or more of the following validated tools 1:

• Maddrey Discriminant Function (MDF) >32 predicts high 28-day mortality and defines severe disease 1
• MELD score >20 predicts high 90-day mortality 1
• ABIC score category C predicts high 28- and 90-day mortality 1
• Glasgow alcoholic hepatitis score ≥9 predicts high 28-day mortality 1

Before initiating any treatment, obtain cultures of blood, urine, and ascites (if present) regardless of fever presence, as infections are common and significantly worsen outcomes 1. The immune response is impaired in alcoholic hepatitis, placing patients at high risk for bacterial and fungal infections 1.

Management Algorithm by Disease Severity

Severe Alcoholic Hepatitis (MDF ≥32 or MELD >20)

Pharmacologic therapy:

• Prednisolone 40 mg orally daily should be given to improve 28-day mortality in patients without contraindications 2
• Consider adding intravenous N-acetylcysteine (NAC) to prednisolone, as this combination may improve 30-day survival 2
• Reassess response at day 7 using the Lille score to identify non-responders and guide continuation of corticosteroids 2

Absolute contraindications to corticosteroids include active hepatitis B infection, tuberculosis, or other serious active infections 1. However, emerging evidence suggests that previously considered absolute contraindications (such as controlled infection, acute kidney injury, or gastrointestinal bleeding) may be relative once these conditions are stabilized 3.

Critical pitfall: Pentoxifylline is no longer recommended for treatment of alcoholic hepatitis, as high-quality evidence (including the STOPAH trial) failed to demonstrate survival benefit 2.

Moderate Alcoholic Hepatitis (MDF <32 and MELD <20)

Supportive care is the primary approach 1:

• Alcohol abstinence counseling and support 1
• High-protein diet supplemented with B vitamins and folic acid 1
• No corticosteroid therapy indicated 1

Universal Management Principles

Nutritional Support (All Patients)

Aggressive nutritional repletion is mandatory 2, 1:

• 1-1.5 g protein per kg body weight daily 1
• 30-40 kcal per kg body weight daily 1
• Enteral nutrition is preferred over parenteral nutrition 1
• If oral intake is inadequate due to anorexia or altered mental status, place a feeding tube for enteral feeding 1
• Parenteral nutrition alone is inadequate 1

Alcohol Abstinence

Complete abstinence is essential for long-term survival 2, 1. Without abstinence, 90-day mortality reaches 40-50% 1. Methods to support abstinence should be implemented immediately 2.

Monitoring and Complication Prevention

Avoid nephrotoxic drugs, including diuretics, as acute kidney injury is an early manifestation of multi-organ failure 1. The presence of SIRS on admission indicates increased risk of multi-organ failure syndrome, which carries very high mortality 1.

Use iodinated contrast dye cautiously during imaging, as it increases acute kidney injury risk 1.

Hospitalization Criteria

Admit patients with severe alcoholic hepatitis or inadequate social/medical support to encourage abstinence, restore nutrition, and exclude serious infections 1.

Liver Transplantation Consideration

Patients with severe alcoholic hepatitis, particularly those with MELD >26, good insight into their alcohol use disorder, and strong social support should be referred for liver transplantation evaluation, as 90-day mortality is extremely high 1. Alcoholic liver disease is now a leading indication for liver transplantation in the United States 2.

Treatment Duration and Response Assessment

Corticosteroid benefits are modest and limited to <28 days 1. Methylprednisolone does not improve survival beyond 28 days 1. The appropriate duration remains controversial, but reassessment at day 7 with the Lille score is essential to identify non-responders who should discontinue therapy 2.

Therapies to Avoid

Do not use the following agents, as they have failed to demonstrate benefit or caused harm 2:

• Pentoxifylline (conflicting data, high-quality trials negative) 2
• TNF-α inhibitors (infliximab, etanercept) - trials terminated early due to infection-related mortality 2
• Extracorporeal cellular therapy - no survival benefit 2